Editorials

Hyperuricemia, Gout, and Lifestyle Factors
E. Roddy ...............................................................1689

A Little Citrus Might Go a Long Way!
A.C. Gelber ..........................................................1692

Rheumatoid Arthritis and Lung Cancer: You Probably Heard It Before
H. Kallberg ..........................................................1695

Articles

TNF-α –1031 T/C Polymorphism Is Associated with Smaller and More Proatherogenic LDL Particles in Patients with RA
J-C. Vallvé, S. Paredes, J. Girona, et al .............................1697

Risk of Development of Lung Cancer Is Increased in Patients with RA: A Large Case Control Study in US Veterans
R. Khurana, R. Wolf, S. Berney, G. Caldito, S. Hayat, S.M. Berney ...................................................1704

Patients with RA Treated with MTX: Concentrations of Steady-state Erythrocyte MTX Correlate to Plasma Concentrations and Clinical Efficacy
N. Hornung, T. Ellingsen, J. Attermann, K. Stengaard-Pedersen, J.H. Poulsen .............................................1709

Downregulation of RCAS1 and Upregulation of Cytotoxic T Cells Affects Synovial Proliferation and Apoptosis in RA
S. Yoshida, F. Higuchi, Y. Ishibashi, et al ..............................1716

SLC22A4 Polymorphism and RA Susceptibility: A Replication Study in a Japanese Population and a Metaanalysis
Y. Okada, M. Mori, R. Yamada, et al ..................................1723

Short-term Influence of Adalimumab on Work Productivity
Outcomes in Patients with RA

Predictors of Discontinuation of TNF Inhibitors in Patients with RA
S.K.Agarwal, R.J. Glass, N.A. Shadick, et al ......................1737

Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active RA and Inadequate Response to TNF-α Antagonists
M. Vera-Llonch, E. Massarotti, F. Wolfe, et al ..................1745

Clear Associations Between Demographic and Psychosocial Factors and HRQOL in Patients with Early Inflammatory Joint Complaints
G.A. Geuskens, A. Burdorf, A.W.M. Evers, J.M.W. Hazes ............................1754

Decreased Recent Thymus Emigrant Number Is Associated with Disease Activity in SLE
Q.F. Vieira, C. Kayser, E.G. Kallas, L.E.C. Andrade ..................1762

Uprgulation of aPL Following Cyclophosphamide Therapy in Patients with SLE
P.G. Vlachoyiannopoulos, S.P. Toya, G. Katsiflis, E. Zintzaras, A.G.Tzioufas, H.M. Moutsopoulos ......................................1768

Cognitive Function in a SLE Inception Cohort
M. Petri, M. Naigbuddin, K.A. Carson, et al ........................1776

The Role of Neighborhood and Individual Socioeconomic Status in Outcomes of SLE
L. Trupin, M.C. Tonner, J. Yazdany, et al .............................1782

Novel Cardiovascular Risk Factors in Premature Coronary Atherosclerosis Associated with SLE

Relationship Between Caseload Volume and Outcome for SLE Treatment: The Experience of Taiwan
T-F. Wang, H-C. Lin ..................................................1795

Statin: Potentially Useful in Therapy of SSc-related Raynaud’s Phenomenon and Digital Ulcers
A. Abou-Raya, S. Abou-Raya, M. Helmi ................................1801

Th1 and Th2 Chemokine Serum Levels in SSc in the Presence or Absence of Autoimmune Thyroiditis
A. Antonelli, C. Ferrini, P. Fallahi, et al ..............................1809

Prevalence of Exercise Pulmonary Arterial Hypertension in Scleroderma
J.L. Callejas-Rubio, E. Moreno-Escobar, P.M. de la Fuente, et al .............................1812

No Association Between SSc and C77G Polymorphism in the Human PTPRC (CD45) Gene
H. Kirsten, M. Blume, F. Emmrich, et al .............................1817

Association of Psoriasis (S100A7) with Clinical Manifestations of SSc: Is Its Presence in Whole Saliva a Potential Predictor of Pulmonary Involvement?
C. Baldini, L. Giusti, L. Bazzichi, et al ..............................1820

Clinical Significance of Serum Hyaluronan Levels in SSc: Association with Disease Severity
A. Yoshizaki, Y. Iwata, K. Komura, et al ..............................1825

Low versus High-dose Iloprost Therapy Over 21 Days in Patients with Secondary Raynaud’s Phenomenon and SSc: A Randomized, Open, Single-center Study
A. Kawald, G.R. Burmester, D. Huscher, C. Sunderkötter, G. Riemeikasten ................................................1830

Clinical Features of Hemophagocytic Syndrome in Patients with Dermatomyositis
N. Yajima, K. Wakabayashi, T. Odai, et al ..............................1838

Soluble ECAM and Their Relationship to Disease Activity in Takayasu’s Arteritis
N.K. Tripathy, V. Chandran, N.K. Garg, N. Sinha, S. Nityanand .............................1842

Contents continued on page ii